Compare GSK plc (GSK) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Texas Instruments Incorporated — how do they compare? GSK plc trades at $50.42 (market cap $102.60B), while Texas Instruments Incorporated trades at $278.12 (market cap $256.84B). The key difference: Texas Instruments Incorporated is far larger — about 2.5× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | TXN | |
|---|---|---|
Market Cap | $102.60B | $256.84B |
Sector | Health | Technology |
52-Week High | $61.18 | $332.35 |
52-Week Low | $38.22 | $153.33 |
Enterprise Value | $123.04B | $263.89B |
Dividend Yield | 3.57% | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Texas Instruments (TXN) trades at $280.44, down 1.97% on the day, with a bullish technical signal from moving averages. Recent earnings show beats in Q1 and Q2 2026, with Q3 expected at $2.37 EPS. The company maintains strong profitability with a 31.11% net margin and a 34.97% ROE, though valuation ratios like a P/E of 42.74 appear elevated. Positive sentiment is driven by AI data center demand and a smooth CFO transition announced in June 2026.
Outlook is cautiously optimistic with a consensus price target of $334.75, implying 19% upside, supported by AI growth and operational leverage. Risks include high debt-to-asset ratio of 40.61% and competitive pressures in semiconductors. Investors should weigh strong cash flow and dividend yield against valuation concerns for long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
